Clinical Trials Sponsored by Kythera Biopharmaceuticals

Total 879 results

Anthera Pharmaceuticals

Withdrawn

CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis

Systemic Lupus Erythematosus
Anthera Pharmaceuticals

Withdrawn

BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis (BIANCA-SC)

Microscopic Polyangiitis | Granulomatosis With Polyangiitis
Anthera Pharmaceuticals

Withdrawn

BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy

IgA Nephropathy
Anthera Pharmaceuticals

Terminated

Phase III ALTU-135 CP Safety Trial (DIGEST CP)

Exocrine Pancreatic Insufficiency

United States
Anthera Pharmaceuticals

Completed

Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency (DIGEST)

Cystic Fibrosis | Exocrine Pancreatic Insufficiency

United States
Anthera Pharmaceuticals

Completed

PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus (PEARL-SC)

Systemic Lupus Erythematosus

United States, Argentina, Brazil, Chile, Colombia, Hong Kong, India, Mexico, Peru, Philippines, Taiwan
Anthera Pharmaceuticals

Completed

PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease (PLASMA 2)

Coronary Artery Disease

United States
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)

Nonalcoholic Steatohepatitis (NASH)

United States, Australia, Puerto Rico
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States, Australia, New Zealand
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Phase 2 Study of NGM282 in Patients With Type 2 Diabetes

Diabetes Mellitus

Australia, New Zealand
Samyang Biopharmaceuticals Corporation

Recruiting

A Study Comparing SYB PDO Thread and MINT Lift® for Temporary Nasolabial Fold Improvement

Nasolabial Folds

Korea, Republic of
HighField Biopharmaceuticals Corporation

Recruiting

A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors

Solid Tumors, Adult

China, United States
Gracell Biopharmaceuticals, Inc.

Recruiting

A Study of GC012F, a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma

Relapsed/ Refractory Multiple Myeloma

United States
Kangpu Biopharmaceuticals, Ltd.

Active, not recruiting

Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE (Lupus)

SLE; Drug

United States
NGM Biopharmaceuticals, Inc

Completed

A Study of NGM621 in Participants With Geographic Atrophy (CATALINA)

Geographic Atrophy

United States
Equilibre Biopharmaceuticals B.V.

Active, not recruiting

Safety, Tolerability, and Exploratory Efficacy of Adjunctive EQU-001 for Seizures in Adults With Epilepsy

Epilepsy

United States, Israel
RegeneRx Biopharmaceuticals, Inc.

Withdrawn

A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction

ST Elevation Myocardial Infarction | Acute Myocardial Infarction | STEMI
Noorik Biopharmaceuticals AG

Terminated

A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis

Cirrhosis | Ascites | Portal Hypertension

Spain
NGM Biopharmaceuticals, Inc

Completed

Study of NGM621 in Participants With Geographic Atrophy

Geographic Atrophy

United States
Alder Biopharmaceuticals, Inc.

Completed

A Multicenter Assessment of ALD403 in Frequent Episodic Migraine (PROMISE 1)

Migraine Disorders

United States, Georgia
NGM Biopharmaceuticals, Inc

Completed

Study of Aldafermin (NGM282) in Participants With Impaired Renal Function

Impaired Renal Function

United States
Ascend Biopharmaceuticals Ltd

Completed

A Study of the Efficacy and Safety of ASN-002 in Adult Patients With Low-risk Nodular Basal Cell Carcinoma (ASN-002-001)

Basal Cell Nevus Syndrome | Skin Neoplasm | Nodular Basal Cell Carcinoma of Skin

Australia
Samyang Biopharmaceuticals Corporation

Completed

A Trial to Determine the Maximum Tolerated Dose and Evaluate the Safety and Pharmacokinetics of Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel, in Subjects With Advanced Solid Malignancies

Advanced Solid Malignancies

Korea, Republic of
Samyang Biopharmaceuticals Corporation

Completed

Pharmacokinetic Study of Docetaxel-PNP and Taxotere to Treat Patient With Advanced Solid Cancer (DOPNP201)

Solid Tumor
Alder Biopharmaceuticals, Inc.

Completed

Safety, Efficacy and Pharmacokinetics of ALD403

Migraine

United States
NGM Biopharmaceuticals, Inc

Completed

Phase 1 SAD and MAD Study of NGM282 in Healthy Adult Participants

Diabetes Mellitus

Australia
Samyang Biopharmaceuticals Corporation

Completed

Relative Bioavailability Study of Lipidil® Supra (Fenofibrate 160mg) Versus SYO-0805 (Fenofibrate 65mg)

Hyperlipidemia

Korea, Republic of
Nabi Biopharmaceuticals
GlaxoSmithKline

Completed

Pharmacoeconomic Assessment in Nabi-4514 and Nabi-4515 Phase 3 Studies

Smoking Cessation

United States
RegeneRx Biopharmaceuticals, Inc.

Completed

Study of Thymosin Beta 4 in Patients With Pressure Ulcers

Pressure Ulcers

United States
Revotar Biopharmaceuticals AG

Completed

Safety and Efficacy Study of Bimosiamose Cream to Treat Psoriasis

Psoriasis

Germany
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals Australia Pty Ltd

Completed

Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis

Primary Biliary Cirrhosis

United States, Australia
Sound Biopharmaceuticals Ltd.

Recruiting

Study in Patients With Advanced Solid Malignancies to Evaluate the Safety of FTL001

Solid Tumor

China
Samyang Biopharmaceuticals Corporation

Not yet recruiting

A Study Comparing Lafullen15 and Lafullen for Temporary Nasolabial Fold Improvement

Nasolabial Folds
Samyang Biopharmaceuticals Corporation

Recruiting

Clinical Trial to Evaluate the Safety and Efficacy of MONOFIX® PGCL Suture in Laparoscopic Surgery

Laparoscopic Hysterectomy

Korea, Republic of
Samyang Biopharmaceuticals Corporation

Recruiting

Study to Evaluate the Safety of Nanoxel M Inj.

Breast Cancer | Head and Neck Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Non-small Cell Lung Cancer

Korea, Republic of
Samyang Biopharmaceuticals Corporation

Terminated

Compare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer

Breast Cancer

Korea, Republic of
Ascend Biopharmaceuticals Ltd

Completed

Safety and Efficacy of ASN-002 Combined With a Hedgehog Pathway Inhibitor

Basal Cell Nevus Syndrome | Basal Cell Carcinoma

Australia
Noorik Biopharmaceuticals AG

Terminated

A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19

Covid19 | Hypoxemia

Spain, Croatia
HighField Biopharmaceuticals Corporation

Terminated

Evaluate the Safety, Tolerability and PK of HF1K16 in Healthy Volunteers

Healthy

United States
NGM Biopharmaceuticals, Inc

Completed

Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function

Impaired Hepatic Function

United States
NGM Biopharmaceuticals, Inc

Completed

Study of NGM395 in Adult Participants

Obesity | NAFLD

Australia
Alder Biopharmaceuticals, Inc.

Completed

An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine (PREVAIL)

Migraine Disorder

United States
NGM Biopharmaceuticals, Inc

Completed

Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects

Cachexia

Australia
NGM Biopharmaceuticals, Inc

Completed

Study of NGM313 in Obese Participants

Obese

United States
Samyang Biopharmaceuticals Corporation

Unknown

Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas

Metastatic Adenocarcinoma of the Pancreas | Recurrent Adenocarcinoma of the Pancreas

Korea, Republic of
NGM Biopharmaceuticals, Inc

Completed

Phase 1 Study of NGM313 in Healthy Adult Participants

Obesity

Australia
Samyang Biopharmaceuticals Corporation

Completed

A Trial of Paclitaxel (Genexol®) and Cisplatin Versus Paclitaxel Loaded Polymeric Micelle (Genexol-PM®) and Cisplatin in Advanced Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

Korea, Republic of
Samyang Biopharmaceuticals Corporation

Completed

A Trial to Evaluate Efficacy and Safety of the Combination Therapy of Genexol®-PM Plus Carboplatin® Compared to Genexol® Plus Carboplatin® as a Firstline Treatment in Subjects With Ovarian Cancer (GPMOC202)

Ovarian Cancer

Korea, Republic of
Samyang Biopharmaceuticals Corporation

Completed

Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer

Pancreatic Cancer
Samyang Biopharmaceuticals Corporation

Completed

Study of Capsaicin Patch for the Management of Peripheral Neuropathic Pain

Postherpetic Neuralgia | Peripheral Nerve Injury

Korea, Republic of

3

Subscribe